Rigel Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: South San Francisco CA United States (1996)

Organization Overview

First Clinical Trial
2005
NCT00115089
First Marketed Drug
2018
fostamatinib
First NDA Approval
2018
fostamatinib
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Rigel Pharmaceuticals | Rigel Pharmaceuticals, Inc. | Rigel Pharmaceuticals, Inc., Chief Medical Officer | RIGEL PHARMS INC